Apixaban in Atrial Fibrillation From Bleeding Cows to 21st Century Medicinal Chemistry
Stroke 42:2376-2378, Cucchiara, B.L.,et al, 2011
Rivaroxaban versus Warfarin in Nonvavular Atrial Fibrillation
NEJM 365:883-891, 952, Patel, M.R.,et al, 2011
Apixaban versus Warfarin in Patients with Atrial Fibrillation
NEJM 365:981-992,1052, Granger, C.B.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
New Alternative to Warfarin May Help Reduce Stroke Risk in Patients With AF
JAMA 305:25-26, Mitka,M., 2011
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Percutaneous Vascular Interventions for Acute Ischemic Stroke
Stroke 42:e31-e32, ORourke,K.,et al, 2011
Dabigatran Etexilate - A Novel, Reversible, Oral Direct Thrombin Inhibitor: Interpretation of Coagulation Assays and Reversal of Anticoagulant Activity
Thromb Hemost 103:1116-1127, van Ryn,J.,et al, 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge
Arch Neurol 65:1169-1173,1157, Hallevi,H.,et al., 2008
Antithrombotic and Interventional Treatment Options in Cardioembolic Transient Ischaemic Attack and Ischaemic Stroke
JNNP 78:14-24, McCabe,D.J.H. &Rakhit,R.D., 2007
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
The Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin for the Prevention of Venous Thromboembolism After Acute Ischaemic Stroke (PREVAIL Study): An Open-Label Randomised Comparison
Lancet 369:1347-1355, Sherman,D.G.,et al, 2007
Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trial
Stroke 38:2965-2971, Ford,G.A.,et al, 2007
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
JAMA 293:699-706, OBrien,C.L. &Gage,B.F., 2005
Ximelagatran--Promises and Concerns
JAMA 293:736-739, Gurewich,V., 2005
Anticoagulants for Acute Ischemic Stroke
Stroke 35:2916-2917, Sandercock,P.,et al, 2004
Direct Thrombin Inhibition
Stroke 35:1519-1522, Elkind,M.S.V. &Sacco,R.L., 2004
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
Spinal and Epidural Hematoma and Low-Molecular-Weight Heparin
NEJM 338:1774-1775, Wysowski,D.K.,et al, 1998
Anticoagulation Therapy in Pediatric Patients with Sinovenous Thrombosis,A Cohort Study
Arch Neurol 55:1533-1537, deVeber,G.,et al, 1998
Epidural/Spinal Hematoma with Low Molecular Weight Heparin & Spinal/Epidural Anesth or Spinal Puncture
FDA Advisory, Dec 151997., , 1997
A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion
NEJM 394:442-450, Ryan,S.J.,et al, 2026
Left Atrial Appendage Closure - Another Overused Method in Cardiology?
NEJM 394:1336-1338, Widimsky,P, 2026
Cerebral Amyloid Angiopathy
NEJM 394:1836-1845, Greenberg,S.M., 2026
Endovascular Therapy for Medium-Vessel Occlusion Stroke - Narrowing the Target Population
NEJM 394:1955-1957,1894, Ospel,J.M. & Hill, M.D., 2026
Anticoagulant Usage and Risk of Thromboembolic Events After Ischemic Stroke in Adults with Cancer
Neurol 105:e214325, Balali,P.,et al, 2025
Outcomes of Patients with Embolic Stroke of Undetermined Source Treated with Antiplatelet Agents or Anticoagulation, A Multicenter Cohort Study
Neurol 105: e213876, Seigler,J.E.,et al, 2025
Residual Risk of Recurrent Stroke Despite Anticoagulation in Patients with Atrial Fibrillation,A Systematic Review and Meta-Analysis
JAMA Neurol 82:696-705, McCabe,J.J.,et al, 2025
Endovascular Treatment in Acute Ischemic Stroke Due to Occlusion of Medium or Distal Vessels
Neurol 105:e214015, Palaiodimou,L.,et al, 2025
Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke
NEJM 393:1191-1201, Tao,C.,et al, 2025
Clinicopathologic Conference, Chagas Disease
NEJM 393:1216-1225, Case 27-2025, 2025
Endovascular Thrombectomy Versus Best Medical Therapy for Large Vessel Occlusion Stroke Beyond 24 Hours: A Systematic Review and Meta-Analysis
Stroke 56:3127-3137, Rodriguez-Caliemnes,A.,et al, 2025
Timing and Safety of Anticoagulation Reinitiation After Intracranial Hemorrhage in Patients with Mechanical Valves
Neurol 105:e214184, DAnna,L.,et al, 2025
Intravenous Thrombolysis Use Before Inter-Facility Transfer for Thrombectomy:Association with Efficacy and Safety Outcomes
Ann Neurol 98:871-880, Seners,P.,et al, 2025
Spectrum of Intracranial Hemorrhages in Cerebral Venous Thrombosis, A Pictorial Case Series and Review of Pathophysiology and Management
Neurologist 30:45-51, Jha,S.,et al, 2025
Left Atrial Appendage Closure After Ablation for Atrial Fibrillation
NEJM 392:1277-1287, Wazni,O.M.,et al, 2025
Anticoagulation or Antiplatelet Therapy for Device-Detected Atrial Fibrillation
NEJM 392:1749-1751, Gorey,S., 2025
Aspirin Continuation or Discontinuation in Surgically Treated Chronic Subdural Hematoma, A Randomized Clinical Trial
JAMA Neurol 82:551-559, Kamenova,M.,et al, 2025
Left Atrial Appendage Occlusion and Its Role in Stroke Prevention
Stroke 56:1928-1937, Seiffge,D.J.,et al, 2025
Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage
JAMA Neurol 8:363-372, Sheth,K.M.,et al, 2024
Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Replacement:A Review
Stroke 55:2754-2764, Patel,K.P.,et al, 2024
Anticoagulation vs Antiplatelets Across Subgroups of Embolic Stroke of Undetermined Source
Neurol 103:e209949, Grannam,M.,et al, 2024
Timing of Anticoagulation Resumption and Risk of Ischemic and Hemorrhagic Complications in Patients with ICH and Mechanical Heart Valves
Neurol 103:e209664, Sakusic,A.,et al, 2024
Recurrent Ischemic Stroke in Patients with Atrial Fibrillation Whle Receiving Oral Anticoagulants
JAMA Neurol 81:805-813, Hindsholm,M.F.,et al, 2024